GlassScriptPhysician profile
Laura Redenius
NPI 1558119784
$1,454.01
in general payments reported to CMS, 2019-2025
18 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $296 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $226.14 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $191.11 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $178.59 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $169.50 | 2024-2025 | |
| Radius Health, INC. | $117.35 | 2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.97 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $77.64 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $74.74 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.58 | 2024-2025 | Xifaxan |
| Amgen INC. | $53.67 | 2025 | Evenity, Repatha |
| Sumitomo Pharma America, INC. | $43.26 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $29.80 | 2024 | Eliquis |
| Inspire Medical Systems, INC. | $25.51 | 2025 | Inspire |
| Electromed, INC. | $24.09 | 2025 | Smartvest |
| Corcept Therapeutics | $22.20 | 2025 | Korlym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $20.26 | 2025 | Immunocap |
| Pfizer INC. | $14.01 | 2024 | |
| Ibsa Pharma INC. | $13.59 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Redenius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.